Gainers

• DBV Technologies (NASDAQ:DBVT) stock moved upwards by 20.0% to $12.0 during Wednesday's pre-market session. The company's market cap stands at $273.6 million.
• Radiopharm Theranostics (NASDAQ:RADX) shares increased by 15.03% to $6.35. The market value of their outstanding shares is at $42.9 million.
• Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 12.67% to $4.0. The company's market cap stands at $3.8 million.
• Shoulder Innovations (NYSE:SI) stock moved upwards by 11.39% to $13.98. The company's market cap stands at $255.5 million.
• Aspire Biopharma Hldgs (NASDAQ:ASBP) shares rose 11.01% to $0.23. The company's market cap stands at $10.2 million.
• Intensity Therapeutics (NASDAQ:INTS) shares moved upwards by 9.06% to $0.26. The company's market cap stands at $11.9 million.

Losers

• Fortress Biotech (NASDAQ:FBIO) stock declined by 28.0% to $2.66 during Wednesday's pre-market session. The market value of their outstanding shares is at $109.9 million.
• Palisade Bio (NASDAQ:PALI) shares declined by 13.92% to $0.74. The company's market cap stands at $8.0 million.
• Enanta Pharma (NASDAQ:ENTA) stock fell 11.7% to $10.57. The market value of their outstanding shares is at $255.8 million.
• NuCana (NASDAQ:NCNA) shares declined by 8.16% to $4.26. The market value of their outstanding shares is at $1.7 billion.
• Barinthus Biotherapeutics (NASDAQ:BRNS) shares declined by 8.01% to $1.15. The company's market cap stands at $50.8 million.
• Fortress Biotech (NASDAQ:FBIOP) shares decreased by 7.83% to $8.48. The company's market cap stands at $31.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.